eShowcase: Data JumpStart
Data JumpStart helps companies deploy standardization and conversion solutions
Data JumpStart helps companies deploy standardization and conversion solutions
Octagon Research Solutions, Inc.'s (Wayne, PA) Data JumpStart assists companies in establishing data standards across their organization, as well as their outsourcing partners. Data JumpStart is an SDTM and CDISC compliant collection of documents, libraries, and templates.
It includes Case Report Form Library, a collection of 12 standard case report forms that leverage CDISC SDTM Nomenclature; Annotated Case Report Forms with SDTM variable names; Variable Names Library, which details variable names that can be used within each dataset categorized by dataset; CDISC SDTM compatible laboratory specifications for central lab vendors; Standard Query Library, which consists of approximately 50 standardized queries to provide consistent quality data; and Comprehensive Data Management Plan template, which includes 60 pages of expert guidance for the development of a data management plan.
Octagon Research Solutions, Inc., (610) 535-6500, www.octagonresearch.com
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Zerlasiran Achieves Significant Sustained Reduction in Lipoprotein(a) Levels with Infrequent Dosing
November 20th 2024Zerlasiran, a novel siRNA therapy, demonstrated over 80% sustained reductions in lipoprotein(a) levels with infrequent dosing in the Phase II ALPACAR-360 trial, highlighting its potential as a safe and effective treatment for patients at high risk of cardiovascular disease.
